HSPTR has completed its business combination with SL Bio, transforming from a SPAC searching for targets into a subsidiary of a new public company trading on Nasdaq.
This represents the successful culmination of HSPTR's SPAC mission, with shareholders now owning shares in the combined entity (PubCo) that will trade on Nasdaq following the merger completion. The appointment of William Wang Ching-Dong as sole director and the removal of all previous deadline language indicates the transaction has closed, ending HSPTR's existence as an independent acquisition vehicle.
The balance sheet shows a dramatic reduction in current assets from $720K to $30K, reflecting the substantial depletion of cash resources likely used to complete the business combination transaction. This near-complete drawdown of liquid assets is consistent with a SPAC that has successfully consummated its target acquisition and distributed proceeds to facilitate the merger.
Current assets declined 95.9% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →